CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / (NASDAQ:MRNA) today announced that the first participant in the U.S. has ...

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the ...

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...

Moderna also anticipates reporting interim Phase III CMVictory data on its mRNA-1647 candidate within the year and is preparing to commence a Phase III trial for its norovirus vaccine mRNA-1403.

Moderna also anticipates reporting interim Phase III CMVictory data on its mRNA-1647 candidate within the year and is preparing to commence a Phase III trial for its norovirus vaccine mRNA-1403.

[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 ...

Data from this study is expected as early as 2024-end. Management announced plans to start a pivotal late-stage study on its norovirus vaccine candidate mRNA-1403. It is also on track to begin ...

[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 years ...